Literature DB >> 10762697

Opioid receptor endocytosis and activation of MAP kinase pathway.

N Trapaidze1, I Gomes, S Cvejic, M Bansinath, L A Devi.   

Abstract

Opioid receptors, members of the G-protein coupled receptor (GPCR) super family, bind to endogenous opioid peptides or opiate drugs and induce a wide variety of signal transduction processes by inhibiting adenylyl cyclase, modulating cation channels, and activating the mitogen-activated protein (MAP) kinases. Similar to other GPCRs, agonist binding causes rapid internalization and down-regulation of opioid receptors. The interdependence between receptor endocytosis and activation of MAP kinase pathway are increasingly being examined. We have examined these using ligands that exhibit differential extent of endocytosis as well as mutants of mu and delta opioid receptors that are unable to internalize. We find that ligands, including morphine, that do not induce receptor internalization are able to stimulate MAP kinase phosphorylation not only in heterologous cells but also in neuronal cell lines that express endogenous mu and delta receptors. Moreover, mutant receptors that fail to undergo agonist-mediated internalization are able to efficiently phosphorylate MAP kinases. Taken together, these data are consistent with the notion that the activation of MAP kinase pathway is an internalization independent phenomenon in the case of opioid receptors and that GPCR internalization and activation of MAP kinase are governed by complex regulatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762697     DOI: 10.1016/s0169-328x(00)00002-4

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  30 in total

1.  Heterodimerization of mu and delta opioid receptors: A role in opiate synergy.

Authors:  I Gomes; B A Jordan; A Gupta; N Trapaidze; V Nagy; L A Devi
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

Review 2.  Post-transcriptional regulation of opioid receptors in the nervous system.

Authors:  Li-Na Wei; Ping-Yee Law; Horace H Loh
Journal:  Front Biosci       Date:  2004-05-01

3.  Exploring the Backbone of Enkephalins To Adjust Their Pharmacological Profile for the δ-Opioid Receptor.

Authors:  Arnaud Proteau-Gagné; Véronique Bournival; Kristina Rochon; Yves L Dory; Louis Gendron
Journal:  ACS Chem Neurosci       Date:  2010-09-17       Impact factor: 4.418

Review 4.  Advances in opioid pharmacology.

Authors:  Geoffrey K Gourlay
Journal:  Support Care Cancer       Date:  2004-12-21       Impact factor: 3.603

Review 5.  Look before leaping: combined opioids may not be the rave.

Authors:  Mellar P Davis; Susan B LeGrand; Ruth Lagman
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

6.  Extracellular signal-regulated kinase (ERK) inhibition does not prevent the development or expression of tolerance to and dependence on morphine in the mouse.

Authors:  Lionel Moulédous; Miguel F Díaz; Howard B Gutstein
Journal:  Pharmacol Biochem Behav       Date:  2007-07-18       Impact factor: 3.533

Review 7.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

8.  GPR171 is a hypothalamic G protein-coupled receptor for BigLEN, a neuropeptide involved in feeding.

Authors:  Ivone Gomes; Dipendra K Aryal; Jonathan H Wardman; Achla Gupta; Khatuna Gagnidze; Ramona M Rodriguiz; Sanjai Kumar; William C Wetsel; John E Pintar; Lloyd D Fricker; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

9.  In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance.

Authors:  B Aguila; L Coulbault; M Boulouard; F Léveillé; A Davis; G Tóth; A Borsodi; G Balboni; S Salvadori; P Jauzac; S Allouche
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 10.  Thyrotropin receptor-associated diseases: from adenomata to Graves disease.

Authors:  Terry F Davies; Takao Ando; Reigh-Yi Lin; Yaron Tomer; Rauf Latif
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.